

State of California—Health and Human Services Agency California Department of Public Health



Office of AIDS (OA)
AIDS Drug Assistance Program (ADAP)

Management Memorandum Memorandum Number: 2019-13

DATE: May 16, 2019

TO: ADAP ENROLLMENT WORKERS

SUBJECT: **ADDITION OF DORAVIRINE (PIFELTRO™) AND**

DORAVIRINE/LAMIVUDINE/TENOFOVIR DISOPROXIL FUMARATE

(DELSTRIGO™) TO THE ADAP FORMULARY

Effective May 3, 2019, doravirine (Pifeltro[™]) and doravirine/lamivudine/tenofovir disoproxil fumarate (Delstrigo[™]) have been added to the ADAP formulary.

Pifeltro™ is a new non-nucleoside reverse transcriptase inhibitor, which received approval for use in the treatment of HIV-1 infection in combination with other antiretroviral (ARV) medications. Delstrigo™ is a once-daily, fixed-dose combination tablet, which combines doravirine with two nucleoside analog reverse transcriptase inhibitors, lamivudine, and tenofovir disoproxil fumarate. Delstrigo was approved as a complete regimen for the treatment of HIV-1 infection. Both Pifeltro™ and Delstrigo™ were approved for treatment naïve patients and can be taken with or without food. The ADAP Medical Advisory Committee recommended the addition of Pifeltro™ and Delstrigo™ to the ADAP formulary as additional treatment options for HIV-1 infection.

ADAP management requests that you share this information with your clinical leadership team and local prescribers. The <u>ADAP drug formulary</u> has been updated to reflect the addition of Pifeltro[™] and Delstrigo[™]. Access the updated formulary at the following URL: https://cdph.magellanrx.com/member/documents.

If you have any questions regarding the addition of these medications to the ADAP formulary, please contact Cynthia Reed-Aguayo, ADAP Specialist, at (916) 449-5791.

Thank you,

Sandra Robinson, MBA

ADAP Branch Chief

California Department of Public Health